Summary:
A Phase 1, Randomized, Double Blind, Placebo Controlled, Serial Cohort Dose Escalation Study to assess the safety, tolerability, and pharmacokinetics of single oral doses of AT-1082 in Healthy Nonsmoking Adults.
Qualified Participants Must:
• Be 18-55 years old
•
Have BMI between 18-32
•
Be a poor metabolizer of CYP2D6 Enzyme
•
Be a nonsmoker
Qualified Participants May Receive:
Compensation for time and travel.
Transportation provided and No insurance needed.